若羽臣被券商维持“买入”评级，旗下斐萃品牌宣布深度联合研发

Core Viewpoint - The company RuYuchen (003010.SZ) announced adjustments to its share repurchase plan while maintaining the total amount of funds for repurchase between 100 million and 200 million yuan, indicating a strategic focus on growth and shareholder value [1] Group 1: Financial Performance and Projections - The total revenue for 2023 is projected at 1.366 billion yuan, with a year-on-year growth of 12.25%. By 2027, revenue is expected to reach 4.762 billion yuan, reflecting a growth rate of 31.04% [2] - The net profit attributable to shareholders is forecasted to be 54.29 million yuan in 2023, increasing to 302.92 million yuan by 2027, with a significant year-on-year growth of 60.93% in 2023 and 30.37% in 2027 [2] - The earnings per share (EPS) is expected to rise from 0.33 yuan in 2023 to 1.85 yuan in 2027, indicating strong profitability growth [2] Group 2: Industry Trends and Strategic Initiatives - The Chinese government has emphasized the development of the anti-aging industry, which is expected to grow rapidly due to advancements in genetic technology and regenerative medicine [2] - RuYuchen's brand Feicui has established a strategic partnership with Jinan University to create an "Anti-Aging Research Center," focusing on aging mechanisms and regenerative medicine [3] - The company has formed strategic collaborations with leading raw material suppliers to enhance product development, leveraging innovative ingredients like "Ruby Oil" for its multiple health benefits [3] Group 3: Market Position and Growth Drivers - RuYuchen is recognized as a leading digital brand management company in China, successfully expanding into household cleaning and health supplement sectors [3] - The brand Feicui has shown rapid growth, ranking second in the oral beauty nutrition category on Tmall and achieving significant visibility in live streaming on Tmall International [1][3] - East Wu Securities has raised the net profit forecasts for RuYuchen for 2025 and 2026, reflecting confidence in the company's growth trajectory and maintaining a "buy" rating [3]